Market Overview

PiperJaffray Cuts Pacific Biosciences Q1 2016 Revs From $19.1M To $17.6M, Says 'we are now $400K below the Street', Maintains Neutral And $11 PT

Share:

Get News First. Profit Faster

upsell-button
With Benzinga Professional get unlimited access to ALL content! PLUS:
  • REALTIME NEWSFEED
  • REALTIME AUDIO NEWS
  • FULL CALENDAR SUITE
  • CHAT WITH OUR NEWS DESK

Latest Ratings for PACB

DateFirmActionFromTo
Apr 2016First AnalysisInitiates Coverage onOverweight
Apr 2016MKM PartnersInitiates Coverage onNeutral
Feb 2016PiperJaffrayDowngradesOverweightNeutral

View More Analyst Ratings for PACB
View the Latest Analyst Ratings

Posted-In: Analyst Color Reiteration Analyst Ratings

 

Related Articles (PACB)